A biotech running a Phase 2 GLP-1 clinical trial at multiple sites identified a significant number of whole-body DXA scans that were incorrectly acquired and analyzed. After reviewing the scans, Bracken's DXA experts recommended a standardized training program to maintain data integrity and salvage the study...